Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter . The telehealth company is preparing to sell already-allowed popular compounds that patients seek for wellness and longevity benefits despite limited clinical evidence. The plan comes as the FDA decides whether to loosen restrictions on seven different compounds. Last month, the agency held a hearing in which outside advisers recommended easing limits on production and expanding access.